Biglycan (BGN)

Biglycan is a small leucine-rich repeat proteoglycan (SLRP) encoded by the BGN gene on the X chromosome and present in connective tissues such as bone, cartilage, and tendon[2][1]. It comprises a protein core with leucine-rich repeats and two glycosaminoglycan (GAG) chains (dermatan or chondroitin sulfate), typically linked near the protein's N-terminus[2][1]. Biglycan acts both as a **structural component of the extracellular matrix** and as a **modulator of signaling pathways** central to bone formation, immune response, and inflammation[3][1]. It interacts with multiple key molecules—including collagens, growth factors (BMPs, TGF-beta), Toll-like receptors (TLR2, TLR4), and components of the dystrophin-associated glycoprotein complex—and can be released during tissue injury to act as a "danger signal" activating innate immune responses[3]. In mice, biglycan deficiency causes an osteoporosis-like phenotype, and in humans, altered biglycan levels are implicated in bone disorders, cardiovascular disease (via lipoprotein binding), and muscle diseases[2][3][1]. No approved drugs specifically target biglycan, but it is an emerging target of interest for musculoskeletal and inflammatory pathologies.

Other names

proteoglycan-IPG-I

Not directly targeted by approved drugs (as of the latest literature) Potential therapeutic targeting might involve modulation of its interactions with growth factors (e.g., BMPs, TGF-beta) or immune receptors (e.g., Toll-like receptors)